Related Topics News -

     
 Title only   |   Print 
     
康諾亞生物就司普奇拜單抗注射液 東南亞和中亞等18個國家和地區上市註冊和商業化達成許可協議

2026-09-03T  
《大行》里昂升康諾亞生物目標價至104元 上調今明兩年盈測

2026-09-01T  
《大行》大和升康諾亞生物目標價至110元 評級「買入」

2026-08-21T  
《大行》花旗升康諾亞目標價至97.5元 評級「買入/高風險」

2026-08-21T  
康諾亞現升逾6% 中期扭虧擬於上交所科創板上市

2026-08-20T  
《業績》康諾亞生物醫藥中期扭虧賺12.18億元人民幣

2026-08-20T  
康諾亞CM512治療慢性鼻竇炎將啟動三期臨床研究

2026-08-10T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.